Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Candesartan cilexetil
Drug ID BADD_D00347
Description Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for the treatment of heart failure, systolic dysfunction, myocardial infarction and coronary artery disease.
Indications and Usage May be used as a first line agent to treat uncomplicated hypertension, isolated systolic hypertension and left ventricular hypertrophy. May be used as a first line agent to delay progression of diabetic nephropathy. Candesartan may be also used as a second line agent in the treatment of congestive heart failure, systolic dysfunction, myocardial infarction and coronary artery disease in those intolerant of ACE inhibitors.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00796
KEGG ID D00626
MeSH ID C077793
PubChem ID 2540
TTD Drug ID Not Available
NDC Product Code 62559-641; 70771-1207; 17228-0032; 0378-3224; 46708-341; 62559-642; 63629-2126; 62332-341; 62332-342; 68382-191; 68382-193; 70771-1205; 52562-100; 46708-342; 0378-3232; 70771-1206; 46708-060; 46708-343; 60687-119; 60687-130; 62332-343; 17228-0016; 64220-114; 49884-659; 68382-190; 17228-0017; 65372-1128; 49884-658; 63629-2127; 68382-192; 70518-2719; 70518-2884; 60687-241; 62332-060; 62559-643; 0378-3225; 70771-1204; 17228-0018; 72761-002; 49884-661; 62559-640; 0378-3231; 49884-660
UNII R85M2X0D68
Synonyms candesartan cilexetil | 1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate | 1H-benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)- | Parapres | Kenzen | Amias | Blopress | Atacand | TCV 116 | TCV-116
Chemical Information
Molecular Formula C33H34N6O6
CAS Registry Number 145040-37-5
SMILES CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)OC(C)OC(=O)OC6CCCCC 6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dyslipidaemia14.08.04.015---
Restless legs syndrome15.05.03.012; 17.02.07.0080.001262%-
Gastrointestinal toxicity07.08.03.006; 12.03.01.0190.000841%-
Angiopathy24.03.02.007---
Hepatic enzyme increased13.03.04.028---
Cardiac disorder02.11.01.0030.002523%-
Connective tissue disorder10.04.04.026; 15.06.01.006---
Foetal disorder18.03.02.0010.008410%-
Infestation11.09.01.001; 23.11.01.002---
Inflammation08.01.05.007; 10.02.01.0890.002944%-
Limb discomfort15.03.04.014---
Ischaemic stroke17.08.01.018; 24.04.06.0100.001262%-
Malnutrition14.03.02.004---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.002---
Decreased appetite08.01.09.028; 14.03.01.0050.009588%
Feeling of body temperature change08.01.09.0120.001262%-
Erectile dysfunction19.08.04.001; 21.03.01.0070.001682%
Respiratory disorder neonatal18.04.09.002; 22.11.01.0020.000841%-
Blood disorder01.05.01.004---
Adverse drug reaction08.06.01.009---
Bone lesion15.02.04.0160.000841%-
Drug intolerance08.06.01.013---
Diabetic nephropathy05.07.02.003; 14.07.02.003; 20.05.03.011---
Hepatobiliary disease09.01.08.003---
Urine analysis abnormal13.13.02.008---
Renal impairment20.01.03.0100.004794%-
Respiratory tract infection11.01.08.017; 22.07.07.001---
Cystitis noninfective20.03.02.001--
Skin haemorrhage23.06.07.001; 24.07.01.1030.001262%-
The 14th Page    First    Pre   14 15 16    Next   Last    Total 16 Pages